IP Library Granted Patent US 11,060,059
Granted Patent B2
US 11,060,059 · App. 15/284,840 · Granted Jul 13, 2021

Methods of producing T cell populations enriched for stable regulatory T-cells

Inventors: Yong Chan Kim (Rockville, MD); Ethan Shevach (Rockville, MD)
Assignee: THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH
C12N5/0637A61K35/17C12N5/0636A61K2035/124C12N2501/056C12N2501/515
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,060,059
App. No.
15/284,840
Granted
Jul 13, 2021
Kind
B2
Abstract

The present invention provides methods for producing cell populations enriched for stable, regulatory T cells (Tregs). In particular, the invention relates to methods for culturing T cells such that the final culture is enriched for stable, regulatory T cells. It also relates to methods for stabilizing regulatory T cells. Also provided are compositions enriched for stable, regulatory T cells, which are useful for treating individuals in need of such treatment. The methods and compositions disclosed herein can also be used to treat an individual suffering from an immune-mediated disease.

Claims (5)

1. A cell culture composition comprising a population of isolated, human, cells, an anti-CD3 antibody, an anti-CD28 antibody, and an oligonucleotide, wherein the oligonucleotide is between 10 and 300 nucleotides in length, wherein the oligonucleotide is external to the cells, and wherein at least 90% of the cells in the population of isolated, human cells are CD4+, Foxp3+, Helios+, CD25 hi , CD127 lo , regulatory T-cells.

2. The composition of claim 1 , wherein the oligonucleotide comprises a phosphorothioate backbone.

3. The composition of claim 1 , wherein the composition comprises interleukin-2 (IL-2).

4. The composition of claim 3 , wherein the concentration of IL-2 is sufficient to induce expansion of regulatory T-cells.

5. The composition of claim 1 , wherein the oligonucleotide is between 21 and 29 nucleotides in length.

Assignments (2)
SECURITY INTEREST Recorded Jul 18, 2023
From: BOUNCE MERGER SUB II, LLC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 064298/0192 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2016
From: KIM, YONG CHAN; SHEVACH, ETHAN
To: THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES
Reel/Frame 040060/0179 →
Continuity (3)
Division 13716900 · Dec 17, 2012
Provisional Application 61576837 · Dec 16, 2011
Related Publication 20170022478A1 · Jan 26, 2017